Business, energy, technology, markets and global industry news from Business News Today

glioblastoma

PharmaDeviceNews glioblastoma
Infographic showing Phase 3 SURVIVE trial results for SurVaxM, including 233 patients, a 2.5-month median overall-survival difference, a non-significant full-population primary endpoint, and a stronger statistically significant result in patients aged 65 or younger.
Pharma & Biotech

SurVaxM showed a four-month survival gap in younger glioblastoma patients. Can MimiVax overcome the missed primary endpoint?

MimiVax and Roswell Park reported a 2.5-month median overall-survival difference for SurVaxM in the 233-patient SURVIVE trial, but the full-population primary endpoint did not reach statistical significance. A prespecified group aged 65 or younger showed a stronger and statistically significant survival result, leaving the FDA to assess whether the signal is sufficient to define the

Read More
Pharma & Biotech

Can Plus Therapeutics Inc. turn REYOBIQ into a differentiated platform for difficult-to-treat CNS cancers?

Can REYOBIQ change CNS cancer treatment? Discover why Plus Therapeutics Inc.’s latest leptomeningeal metastases data is drawing attention.

Read More
Representative image: Advanced brain PET imaging for glioma assessment, reflecting how Telix Pharmaceuticals Limited’s TLX101-Px could expand standardized FET-PET access for brain cancer diagnosis and treatment decision-making in Europe.
Medical Devices & Diagnostics

Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane

Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.

Read More
Representative image of single-cell tumor analysis and clonal growth profiling, illustrating how SingleCell Biotechnology’s AACR 2026 assay could help link cancer cell behavior to molecular signatures in oncology drug discovery.
Pharma & Biotech

AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling

Read how SingleCell Biotechnology’s AACR 2026 assay could reshape tumor heterogeneity research and oncology drug development.

Read More
Pharma & Biotech

What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research

Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.

Read More
Pharma & Biotech

How ImmunityBio’s ANKTIVA combo is challenging glioblastoma’s immune collapse model

New Phase 2 data suggest ImmunityBio’s ANKTIVA plus CAR-NK combo could restore immune competence in glioblastoma. Find out why it matters.

Read More
Pharma & Biotech

Adaptin Bio prepares Phase 1 glioblastoma trial following preclinical progress in brain cancer candidate

Find out how Adaptin Bio is preparing a Phase 1 glioblastoma trial and why its preclinical progress matters for brain cancer treatment innovation.

Read More
Representative image of GammaTile being implanted during brain tumor surgery, illustrating the intraoperative radiation approach tested in the BRIDGES trial for newly diagnosed glioblastoma.
Medical Devices & Diagnostics

GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients

GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks

Read More
Representative image illustrating targeted radiopharmaceutical therapy in brain cancer, reflecting Curasight’s uTREAT Phase 1 glioblastoma trial and the growing role of theranostics in neuro-oncology research.
Pharma & Biotech

Curasight begins Phase 1 trial of uTREAT in glioblastoma, marking shift to clinical-stage radiopharma development

Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement

Read More
Pharma & Biotech

T-MAXIMUM’s MT027 clears FDA hurdle for glioblastoma in major step for solid tumor CAR-T

T-MAXIMUM’s MT027 CAR-T therapy for glioblastoma enters Phase II after FDA clearance. Find out what this means for solid tumor cell therapy.

Read More